Fortekor Plus

RSS

benazepril / pimobendan

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Fortekor Plus. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Fortekor Plus.

For practical information about using Fortekor Plus, animal owners/keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 06/11/2018

Authorisation details

Product details
Name
Fortekor Plus
Agency product number
EMEA/V/C/002804
Active substance
  • benazepril hydrochloride
  • pimobendan
International non-proprietary name (INN) or common name
benazepril / pimobendan
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QC09BX90
Publication details
Marketing-authorisation holder
Elanco GmbH
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
08/09/2015
Contact address

Heinz-Lohmann-Str. 4
27472 Cuxhaven
Germany

Product information

29/08/2018 Fortekor Plus - EMEA/V/C/002804 - T/0011

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • ACE inhibitors
  • combinations

Therapeutic indication

For the treatment of congestive heart failure due to atrioventricular valve insufficiency or dilated cardiomyopathy in dogs.

Assessment history

How useful was this page?

Add your rating